β-Lactam Antibiotics Renaissance
Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the pro...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-05-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | http://www.mdpi.com/2079-6382/3/2/193 |
id |
doaj-f3b075e6df7e4069a581218298aa5875 |
---|---|
record_format |
Article |
spelling |
doaj-f3b075e6df7e4069a581218298aa58752020-11-25T00:12:07ZengMDPI AGAntibiotics2079-63822014-05-013219321510.3390/antibiotics3020193antibiotics3020193β-Lactam Antibiotics RenaissanceWenling Qin0Mauro Panunzio1Stefano Biondi2ISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, ItalyISOF-CNR Department of Chemistry "G. Ciamician", Via Selmi, 2 I-40126 Bologna, ItalyAllecra Therapeutics SAS, 13, rue de Village-Neuf, F-68300 St-Louis, FranceSince the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors.http://www.mdpi.com/2079-6382/3/2/193β-lactam antibioticsβ-lactamase inhibitorsbacterial infections |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wenling Qin Mauro Panunzio Stefano Biondi |
spellingShingle |
Wenling Qin Mauro Panunzio Stefano Biondi β-Lactam Antibiotics Renaissance Antibiotics β-lactam antibiotics β-lactamase inhibitors bacterial infections |
author_facet |
Wenling Qin Mauro Panunzio Stefano Biondi |
author_sort |
Wenling Qin |
title |
β-Lactam Antibiotics Renaissance |
title_short |
β-Lactam Antibiotics Renaissance |
title_full |
β-Lactam Antibiotics Renaissance |
title_fullStr |
β-Lactam Antibiotics Renaissance |
title_full_unstemmed |
β-Lactam Antibiotics Renaissance |
title_sort |
β-lactam antibiotics renaissance |
publisher |
MDPI AG |
series |
Antibiotics |
issn |
2079-6382 |
publishDate |
2014-05-01 |
description |
Since the 1940s β-lactam antibiotics have been used to treat bacterial infections. However, emergence and dissemination of β-lactam resistance has reached the point where many marketed β-lactams no longer are clinically effective. The increasing prevalence of multidrug-resistant bacteria and the progressive withdrawal of pharmaceutical companies from antibiotic research have evoked a strong reaction from health authorities, who have implemented initiatives to encourage the discovery of new antibacterials. Despite this gloomy scenario, several novel β-lactam antibiotics and β-lactamase inhibitors have recently progressed into clinical trials, and many more such compounds are being investigated. Here we seek to provide highlights of recent developments relating to the discovery of novel β-lactam antibiotics and β-lactamase inhibitors. |
topic |
β-lactam antibiotics β-lactamase inhibitors bacterial infections |
url |
http://www.mdpi.com/2079-6382/3/2/193 |
work_keys_str_mv |
AT wenlingqin blactamantibioticsrenaissance AT mauropanunzio blactamantibioticsrenaissance AT stefanobiondi blactamantibioticsrenaissance |
_version_ |
1725401181586456576 |